BCMA (B-cell maturation antigen) is another ideal target for MM immunotherapy, it is expressed on MM cell lines and malignant plasma cells with high prevalence and its expression increases during disease progression from MGUS to SMM to MM (103–105). This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.